ArticleChina CDC weekly2025
Epidemiological Analysis of the Decline of Myocarditis Burden - China, 1992-2021.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Myocarditis is a prevalent cardiovascular condition that can lead to severe complications. The number of patients with myocarditis, new cases, and deaths in China has been on an upward trend over the years, causing a certain disease burden. What is added by this report?: The overall burden of myocarditis in China is on a downward trend; however, the age-standardized mortality rate (ASMR) and age-standardized disability-adjusted life years (DALYs) rate remain higher than the global average. The age-standardized incidence rate (ASIR), ASMR and age-standardized DALYs rate were higher in men than in women. Individuals younger than 5 years or older than 70 years, the period from 2002-2016, and birth cohort earlier than 1957 were identified as risk factors for myocarditis-related mortality. What are the implications for public health practices?: We should still prioritize the prevention and treatment of myocarditis. It is recommended that primary and secondary prevention efforts focus on individuals younger than 5 years, older than 70 years, and males, with an emphasis on proactive health education and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.